This is an ambidirectional cohort study aiming to develop and validate a risk prediction model for colorectal adenoma recurrence and progression. The study will enroll patients aged 18-75 years who undergo colorectal adenoma resection at the Second Affiliated Hospital of Zhejiang University School of Medicine. A retrospective cohort will include patients treated in the past 10 years with available endoscopic, pathologic, and routine laboratory data. A prospective cohort will be enrolled from the date of ethical approval until December 31, 2030, with collection of epidemiological questionnaire data, lifestyle information, blood and tissue biospecimens, and follow-up outcomes. The primary outcome is adenoma recurrence, with secondary outcomes including advanced adenoma and colorectal cancer. Based on a target of 1,083 evaluable participants (325 events) to ensure adequate model development, and accounting for 15% loss to follow-up, the total planned enrollment is 1,280 participants. The study will validate existing risk models based on traditional adenoma characteristics and establish a novel model incorporating lifestyle factors and systemic inflammatory markers to improve risk stratification and guide surveillance strategies.
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Patients who underwent colonoscopy at our institution, were diagnosed with colorectal adenoma, and underwent adenoma resection.
. Aged between 18 and 75 years.
. Provide written informed consent voluntarily, with willingness to comply with follow-up procedures.
. For the retrospective cohort only: Regular follow-up colonoscopy at our institution within 1 to 5 years after adenoma resection.
Exclusion criteria
. Severe dysfunction of vital organs (e.g., heart, liver, kidney).
. Psychiatric disorders that preclude normal communication or compliance with study procedures.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
colorectal adenoma recurrence
Timeframe: 3-year
Trial details
NCT IDNCT07523035
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University